156 related articles for article (PubMed ID: 17018586)
1. Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast.
Ding L; Kleer CG
Cancer Res; 2006 Oct; 66(19):9352-5. PubMed ID: 17018586
[TBL] [Abstract][Full Text] [Related]
2. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues.
Ding L; Erdmann C; Chinnaiyan AM; Merajver SD; Kleer CG
Cancer Res; 2006 Apr; 66(8):4095-9. PubMed ID: 16618729
[TBL] [Abstract][Full Text] [Related]
3. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene.
Raaphorst FM; Meijer CJ; Fieret E; Blokzijl T; Mommers E; Buerger H; Packeisen J; Sewalt RA; Otte AP; van Diest PJ
Neoplasia; 2003; 5(6):481-8. PubMed ID: 14965441
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.
Umbricht CB; Evron E; Gabrielson E; Ferguson A; Marks J; Sukumar S
Oncogene; 2001 Jun; 20(26):3348-53. PubMed ID: 11423985
[TBL] [Abstract][Full Text] [Related]
5. EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development.
Kunju LP; Cookingham C; Toy KA; Chen W; Sabel MS; Kleer CG
Mod Pathol; 2011 Jun; 24(6):786-93. PubMed ID: 21399615
[TBL] [Abstract][Full Text] [Related]
6. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.
Zeidler M; Kleer CG
J Mol Histol; 2006 Sep; 37(5-7):219-23. PubMed ID: 16855786
[TBL] [Abstract][Full Text] [Related]
7. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
Kleer CG; Cao Q; Varambally S; Shen R; Ota I; Tomlins SA; Ghosh D; Sewalt RG; Otte AP; Hayes DF; Sabel MS; Livant D; Weiss SJ; Rubin MA; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11606-11. PubMed ID: 14500907
[TBL] [Abstract][Full Text] [Related]
8. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia.
Li X; Gonzalez ME; Toy K; Filzen T; Merajver SD; Kleer CG
Am J Pathol; 2009 Sep; 175(3):1246-54. PubMed ID: 19661437
[TBL] [Abstract][Full Text] [Related]
9. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
[TBL] [Abstract][Full Text] [Related]
10. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
11. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
12. [Promoter methylation and mRNA expression of WT1 gene in MCF10 breast cancer model].
Yang JL; Klinkebiel D; Boland MJ; Tang L; Christman JK
Zhonghua Bing Li Xue Za Zhi; 2007 Apr; 36(4):253-8. PubMed ID: 17706117
[TBL] [Abstract][Full Text] [Related]
13. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns.
Boecker W; Buerger H; Schmitz K; Ellis IA; van Diest PJ; Sinn HP; Geradts J; Diallo R; Poremba C; Herbst H
J Pathol; 2001 Nov; 195(4):415-21. PubMed ID: 11745672
[TBL] [Abstract][Full Text] [Related]
14. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
Karanikolas BD; Figueiredo ML; Wu L
Mol Cancer Res; 2009 Sep; 7(9):1456-65. PubMed ID: 19723877
[TBL] [Abstract][Full Text] [Related]
15. Microglandular adenosis with transition to breast carcinoma: a series of three cases.
Lin L; Pathmanathan N
Pathology; 2011 Aug; 43(5):498-503. PubMed ID: 21753716
[No Abstract] [Full Text] [Related]
16. [Recent advances on EZH2 in malignant tumors].
Li J; Fan QH
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):856-8. PubMed ID: 20193471
[No Abstract] [Full Text] [Related]
17. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions.
Weinstat-Saslow D; Merino MJ; Manrow RE; Lawrence JA; Bluth RF; Wittenbel KD; Simpson JF; Page DL; Steeg PS
Nat Med; 1995 Dec; 1(12):1257-60. PubMed ID: 7489405
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.
Hussein YR; Sood AK; Bandyopadhyay S; Albashiti B; Semaan A; Nahleh Z; Roh J; Han HD; Lopez-Berestein G; Ali-Fehmi R
Hum Pathol; 2012 Oct; 43(10):1638-44. PubMed ID: 22436627
[TBL] [Abstract][Full Text] [Related]
19. EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor.
Hwang C; Giri VN; Wilkinson JC; Wright CW; Wilkinson AS; Cooney KA; Duckett CS
Breast Cancer Res Treat; 2008 Jan; 107(2):235-42. PubMed ID: 17453341
[TBL] [Abstract][Full Text] [Related]
20. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
